Dr Philip Brown
Wellcome 4ward North Clinical Fellow
BackgroundPhil completed his medical education at Aberdeen university in 2011 with an intercalated degree in Medical Sciences. After medical school he completed an Academic Foundation post in Middlesbrough and Newcastle before starting an Academic Clinical Fellowship in the North East. He became a member of the Royal College of Physicians in 2015 and started Rheumatology specialist training in 2016. In 2017 he was awarded a Wellcome Clinical PhD Fellowship and has now started his PhD at Newcastle University.
ResearchI am interested in biomarkers to predict response to disease modifying therapies (DMARDs) in inflammatory arthritis. I have recently started a PhD project to investigate biomarkers of response for Methotrexate therapy in Rheumatoid Arthritis. I seek to recruit a cohort of early Rheumatoid Arthritis patients and track the accumulation of drug metabolites in their circulating immune cells. I intend to use this and changes in gene expression during early therapy to try to create a predictive tool to determine which patients respond to methotrexate and which do not.
- Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nature Reviews Rheumatology 2016, 12(12), 731-742.
- Brown PM, Isaacs JD. Rheumatoid Arthritis: An Evolutionary Force in Biologics. Current Pharmaceutical Design 2015, 21(17), 2170-2178.
- Pratt AG, Anderson AE, Lendrem DW, Skelton A, Massey J, Nair N, Diboll J, Hargreaves B, Brown PM, Barton A, Isaacs JD. STAT3-regulated gene expression in circulating CD4+ T cells discriminates RA patients independently of clinical parameters in early arthritis: a validation study. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA.
- Brown PM, Isaacs JD. Rheumatoid arthritis: from palliation to remission in two decades. Clinical Medicine 2014, 14(Suppl. 6), s50-s55.
- Pratt AG, Brown PM, Cockell SJ, Wilson G, Isaacs JD. A CD4+T-Cell Gene Expression Signature Predicts Drug Survival on Methotrexate Monotherapy in Early Rheumatoid Arthritis. In: 33rd European Workshop for Rheumatology Research. 2013, Prague, Czech Republic: BMJ Publishing Group.
- Pratt AG, Brown PM, Cockell SJ, Wilson G, Isaacs JD. A CD4+T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis. In: Annual Scientific Meeting of the American College of Rheumatology (ACR). 2012, Washington, DC, USA: John Wiley & Sons, Inc.